Marco Meglio

Apic Bio plans to initiate a phase 1/2 clinical trial in late 2021 or early 2022 as a multi-center, 3-part study to evaluate APB-102 in patients with SOD1-ALS mutations.

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

The assistant professor of neurology at the Weill Cornell Brain and Spine Center discussed his presentation at AAN 2021 evaluating racial disparities in smoking cessation among stroke survivors.

The Neurolutions IpsiHand Upper Extremity Rehabilitation system is indicated for use in patients with chronic stroke age 18 or older undergoing stroke rehabilitation to facilitate muscle re-education.

Changes in mean use of airway therapy from baseline to week 40 of the open-label extension were minimal for those on solriamfetol.

In addition to a number of positive attributes stemming from telehealth use, most providers claimed they were interested in digitally prescribing headache apps and remotely monitoring patient symptoms.

Three patients included in the study showed positive trends across both I-RODS and Jamar grip strength following treatment with lenalidomide.

Improvement was statistically significant for Cognition and the Global Executive Composite score, where approximately twice as many patients achieved clinically meaningful improvement.

The findings add to the body of evidence for use of antiplatelets in patients with cerebral amyloid angiopathy.

Refractory seizures were more prevalent in hemorrhagic stroke although seizure-free rates were low overall in patients with post-stroke seizures.

Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.

The professor of neurology at Mayo Clinic discussed the need for understanding more about how social determinants of health can impact epilepsy treatment delays.

Patient/guardian decision, adverse event, and physician decision were the 3 noted reasons for discontinuation with either ofatumumab or teriflunomide.

Patients with a previous history of cardiovascular risks experienced similarly low number of cardiovascular events with treatment of fremanezumab compared with placebo.

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.

An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders.

No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.

Serious adverse events occurred in 3.7% and 2.4% of subjects in the subgroups of patients with 1 and 2 or more triptan failures, respectively.

Critically ill patients who were obtunded, stuporous, or comatose had pediatric lateralized epileptiform discharges, and acute brain insults were among many clinical characteristics to benefit from longer EEG.

The ability to feed orally and swallow was maintained by an overwhelming number of patients treated with risdiplam at 24 months.

According to the study authors, future longitudinal studies assessing the evolution of cognitive and cortical excitability changes may provide a greater understanding of the importance of cortical circuits in ALS pathogenesis.

Findings suggest that the neuroprotective therapeutic response from rituximab in patients with relapsing-remitting multiple sclerosis may take up to 12 months.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed solutions to improve disparities in stroke care and the need for future research on social determinants of health.

Overall, 42.4% of patients with Huntington disease reported at least 1 psychiatric or cognitive symptom before motor symptoms, with depression being the most common.

A group of 15 repurposed agents were identified as the best candidates for activity against the network of 20 related and distinct biochemical pathways that are dysregulated in AD-related dementia.

At 6 months, 62% of the 10 kHz spinal cord stimulation treatment group had observed improvement upon investigator-assessed neurological examination, compared to 3% of conventional medical management subjects.

Patients with highly refractory status epilepticus had greater median hospital length stays as well as greater median hospital costs compared to patients with moderate or low refractory status epilepticus.

Treatment with fingolimod followed by alemtuzumab led to an increase in spinal relapses as well as increased risk of secondary autoimmunity.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the issues that remain with enrolling patients into real-world dementia trials and standardizing measures.

Antisense-mediated reduction of mutant FUS protein previously showed prevention of motor neuron loss in an FUS-ALS mouse model.